Palatin Technologies, Inc.
Palatin Technologies, Inc. (Amex: PTN) announced the completion of a Phase I clinical study with PL-3994, a novel long-acting natriuretic peptide receptor agonist A (NPRA) in development for the treatment of acutely decompensated heart failure heart failure (CHF). The phase I trial was a randomized, double-blind, controlled versus placebo, single ascending dose in 26 healthy volunteers who received the drug subcutaneously or placebo.guanosine monophosphate (cGMP), a natural nucleotide messenger. Dosing concluded successfully achieving the primary objective of the study, a reduction in pre-defined systemic blood pressure. No volunteer experienced a serious adverse event or serious. Increased plasma levels of cGMP, increased diuresis (urine excretion) and increased
natriuresis (sodium excretion) were all observed for several hours after a single dose subcutaneously.for presentation when the analysis is complete. We are pleased to confirm that PL-3994 has the profile of biological activity in humans, which is predicted from data from animal models and it was safe and well tolerated, said Dr. Trevor Hallam, Executive Vice President of Research and Palatins development. CHF is the most common cause of hospitalization in the United States for patients over 65 years old and is an area of ​​high unmet medical need for new therapies.
decompensated CHF and plans for a Phase IIa study in these patients later this year begin. Future plans include the development of PL-3994 for the long-term administration in patients with CHF. In
addition, Palatin plans to develop PL-3994 for emergency treatment of acute systemic hypertension. A Phase IIa study in hypertensive subjects is also planned to begin later this year.natural clearance mechanism, natriuretic peptide receptor bodys clearance and greater resistance to an enzyme naturally in the body, found neutral endopeptidase. In animal models, PL-3994 was able to produce diuresis with a limited reduction in
Pages: [1] 2 3